An official website of the United States government 
Activity Outline
FDA Grand Rounds: Analysis of Per and Polyfluoroalkyl Substances (PFAS) in foods- Analytical method development, challenges and successes
April 9, 2020
WO 2: 2047
FDA Grand Rounds: Analysis of Per and Polyfluoroalkyl Substances (PFAS) in foods- Analytical method development, challenges and successes
April 9, 2020
WO 2: 2047
Activity Coordinator:
Devin Thomas (Devin.Thomas@fda.hhs.gov)
Series Description
The FDA Grand Rounds is webcast every other month to highlight cutting-edge research underway across the agency and its impact on protecting and advancing public health. Each session features an FDA scientist presenting on a key public health challenge and how FDA is applying science to its regulatory activities.
Lecture Description
Per- and polyfluoroalkyl substances (PFAS) are a family of human-made chemicals that are found in a wide range of products used by consumers and industry. There are thousands of types of PFAS, some of which have been more widely used and studied than others. Perfluorooctanoic acid (PFOA) and perflurooctanesulfonic acid (PFOS) have been widely studied due to their persistence, distribution, toxicity, and bioaccumulation in humans and the environment. Humans can be exposed to these compounds from environmental contamination (landfills, wastewater treatment plants, the use of aqueous film forming foams (AFFF)), household exposure (upholstery, carpeting, dust) and the diet. In order to assess exposure to PFAS from foods, analytical methodology for the determination of these compounds at part per trillion concentrations is needed.
A QuEChERS LC-MS/MS method has been developed and validated for determination of trace concentrations of PFAS (part per trillion) in several commodities including fruits, vegetables, milk, cheese, grains, meats and other foods. The final method was used to analyze 179 composite food samples collected as part of the FDA's Total Diet Study (TDS) program. TDS foods represent a broad range of foods, including breads, cakes, fruits, dairy, vegetables, meats, poultry, fish, and bottled water, that the average consumer might eat. FDA's recent surveys of foods that are part of the general food supply did not detect PFAS in the vast majority of the foods tested. . These results and the continued analysis of TDS samples will inform the Agency's continued work to understand the occurrence of PFAS in the general food supply.
Details of the method, validation, analytical challenges encountered during the research and results will be presented.
Per- and polyfluoroalkyl substances (PFAS) are a family of human-made chemicals that are found in a wide range of products used by consumers and industry. There are thousands of types of PFAS, some of which have been more widely used and studied than others. Perfluorooctanoic acid (PFOA) and perflurooctanesulfonic acid (PFOS) have been widely studied due to their persistence, distribution, toxicity, and bioaccumulation in humans and the environment. Humans can be exposed to these compounds from environmental contamination (landfills, wastewater treatment plants, the use of aqueous film forming foams (AFFF)), household exposure (upholstery, carpeting, dust) and the diet. In order to assess exposure to PFAS from foods, analytical methodology for the determination of these compounds at part per trillion concentrations is needed.
A QuEChERS LC-MS/MS method has been developed and validated for determination of trace concentrations of PFAS (part per trillion) in several commodities including fruits, vegetables, milk, cheese, grains, meats and other foods. The final method was used to analyze 179 composite food samples collected as part of the FDA's Total Diet Study (TDS) program. TDS foods represent a broad range of foods, including breads, cakes, fruits, dairy, vegetables, meats, poultry, fish, and bottled water, that the average consumer might eat. FDA's recent surveys of foods that are part of the general food supply did not detect PFAS in the vast majority of the foods tested. . These results and the continued analysis of TDS samples will inform the Agency's continued work to understand the occurrence of PFAS in the general food supply.
Details of the method, validation, analytical challenges encountered during the research and results will be presented.
References
- Genualdi, S. and DeJager, L., Determination of 16 Perfluoroalkyl and Polyfluoroalkyl Substances (PFAS) in Food using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), FDA Foods Program Compendium of Analytical Laboratory Methods: Chemical Analytical Manual (CAM), C-010.01, https://www.fda.gov/media/131510/download
Series Objectives
- Discuss the research conducted at the FDA
- Explain how FDA science impacts public health
Learning Objectives After completion of this activity, the participant will be able to:
- Discuss per and polyfluoroalkyl substances and their uses
- Explore the history of PFAS analysis at CFSAN
- Describe analytical methodology and validation
- Explain challenges encountered during method development, validation and sample analysis
- Discuss the results of food analysis and discuss future work
Target Audience
This activity is intended for physicians, pharmacists, nurses, and other scientists within the agency and external scientific communities.
This activity is intended for physicians, pharmacists, nurses, and other scientists within the agency and external scientific communities.
Agenda
Lecture 1 April 9, 2020
Lecture 1 April 9, 2020
| Time | Topic | Speaker |
|---|---|---|
| 12:00 - 1:00 PM EDT | Analysis of Per and Polyfluoroalkyl Substances (PFAS) in foods- Analytical method development, challenges and successes | Lowri Dejager, PhD |
Continuing Education Accreditation
In support of improving patient care, FDA Center for Drug Evaluation and Research is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.
CME
FDA Center for Drug Evaluation and Research designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE
This knowledge-based activity has been assigned ACPE Universal Activity Number JA0002895-0000-20-022-L04-P for 1.00 contact hour(s).
CNE
FDA Center for Drug Evaluation and Research designates this activity for 1.00 contact hour(s).
Requirements for Receiving CE Credit
Physicians, pharmacists, nurses, and those claiming non-physician CME: participants must attest to their attendance and complete the final activity evaluation via the CE Portal (ceportal.fda.gov). For multi-day activities, participants must attest to their attendance and complete the faculty evaluation each day. Final activity evaluations must be completed within two weeks after the activity - no exceptions.
Attention Pharmacists and Pharmacy Techs: Failure to provide your correct NABP AND Date of Birth information, in the required format, may result in the loss of credit for this activity. NABP profile number should be the 6-7 digit profile number assigned by the CPE Monitor and your birth date should be in the MMDD format (e.g. 0721) Do not provide your pharmacy license number. Please click the "My Account" tab and then navigate to "Edit Contact Information" to verify that your information is correct.
Important Note regarding completion of evaluations and receiving credit
Attendees have 14 days from the last day of the activity to log in, complete the required evaluation(s) and attest to your attendance to claim credit.Physicians and nurses may then view/print statement of credit. Pharmacists should log into the CPE monitor 8 weeks after the last session of the activity to obtain their CE credit.
Attendees have 14 days from the last day of the activity to log in, complete the required evaluation(s) and attest to your attendance to claim credit.Physicians and nurses may then view/print statement of credit. Pharmacists should log into the CPE monitor 8 weeks after the last session of the activity to obtain their CE credit.
Disclosure
Faculty
Planning Committee
CE Consultation and Accreditation Team
Faculty
- Dejager, Lowri, PhD, Branch Chief, Center for Food Safety and Applied Nutrition - nothing to disclose
Planning Committee
- Dinatale, Miriam, DO, Team Leader, Food and Drug Administration - nothing to disclose
- Pfundt, Tiffany, PharmD, Program Coordinator, FDA/CDER/OTBB - nothing to disclose
- Thomas, Devin, LCDR, MPH, CHES, Health Promotions Specialist, FDA/OC/OCS/OSPD - nothing to disclose
- Wheelock, Leslie, RN, MS, Director, OSPD, FDA, OC, OCS, OSPD - nothing to disclose
CE Consultation and Accreditation Team
- Bryant, Traci, M.A.T., CE Consultant, FDA/CDER/OEP/DLOD - nothing to disclose
- Zawalick, Karen, CE Team Leader, FDA/CDER/OEP/DLOD - nothing to disclose
Registration Information
Registration is complimentary; therefore refunds are not applicable.
Registration is complimentary; therefore refunds are not applicable.
U.S. Food and Drug Administration